Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + losartan
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of a placebo (an inert substance with no therapeutic effect) and losartan, an angiotensin II receptor blocker (ARB). Losartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By inhibiting this pathway, losartan relaxes blood vessels, lowers blood pressure, reduces the risk of stroke in certain populations with hypertension and left ventricular hypertrophy, and helps protect kidney function in people with type 2 diabetes and hypertension. The inclusion of placebo indicates this combination is used for clinical trial or research purposes rather than as a marketed therapeutic product[1][2][3][7].
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)TYMP (Thymidine phosphorylase)
Beyond the preview
Go deeper on placebo + losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + losartan.